1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Let The U.S. Drug-Coated Balloon Battle Begin

Medtronic gained FDA approval for its drug-coated balloon for the peripheral artery, as expected, and it is now gunning to take share from first-to-market C.R. Bard with the help of impressive clinical data and a formidable Covidien peripheral vascular device sales force.

The U.S. drug-coated balloon market just became competitive. Medtronic PLC announced FDA approval of its IN.PACT Admiral paclitaxel-coated balloon for treating peripheral artery disease Jan. 5, primed for a match up with CR Bard Inc.'s first-to-market Lutonix 035.

Bard had an almost three-month head start in the U.S., launching Lutonix in October. But Medtronic is expected to quickly catch up and overtake Bard based on the strength of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D